Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicenter retrospective case-control study.

Antithyroid drugs Drug-induced vasculitis

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
24 Jun 2023
Historique:
received: 04 03 2023
revised: 26 05 2023
accepted: 11 06 2023
medline: 24 6 2023
pubmed: 24 6 2023
entrez: 24 6 2023
Statut: aheadofprint

Résumé

Data on ANCA-associated vasculitis (AAV) induced by anti-thyroid drugs (ATD) are scarce. We aimed to describe the characteristics and outcome of these patients in comparison to primary AAV. We performed a retrospective multicenter study including patients with ATD-induced AAV. We focused on ATD-induced microscopic polyangiitis (MPA) and compared them with primary MPA by matching each case with 4 controls by gender and year of diagnosis. Forty-five patients with ATD-induced AAV of whom 24 MPA were included. ANCA were positive in 44 patients (98%), including myeloperoxidase (MPO)-ANCA in 21 (47%), proteinase 3 (PR3)-ANCA in 6 (13%), and double positive MPO- and PR3-ANCA in 15 (33%). Main clinical manifestations were skin involvement (64%), arthralgia (51%), and glomerulonephritis (20%). ATD was discontinued in 98% of cases, allowing vasculitis remission in 7 (16%). All the remaining patients achieved remission after glucocorticoids, in combination with rituximab in 11 (30%) or cyclophosphamide in 4 (11%). ATD were reintroduced in 7 cases (16%) without any subsequent relapse. Compared with 96 matched primary MPA, ATD-induced MPA were younger at diagnosis (48 vs. 65 years, P < 0.001), had more frequent cutaneous involvement (54 vs. 25%, P = 0.007), but less frequent kidney (38 vs. 73%, P = 0.02), and a lower risk of relapse (adjusted HR 0.07; 95%CI 0.01-0.65, P = 0.019). ATD-induced AAV were mainly MPA with MPO-ANCA, but double MPO- and PR3-ANCA positivity was frequent. The most common manifestations were skin and musculoskeletal manifestations. ATD-induced MPA were less severe and showed a lower risk of relapse than primary MPA.

Identifiants

pubmed: 37354498
pii: 7206876
doi: 10.1093/rheumatology/kead319
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Julien Culerrier (J)

Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.

Yann Nguyen (Y)

Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.

Omer Karadag (O)

Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.

Sule Yasar Bilge (S)

Division of Rheumatology, Department of Internal Medicine, Vasculitis Research Center, Hacettepe University School of Medicine, Ankara, Turkey.

Tuba Demirci Yildrim (TD)

Department of Rheumatology, Dokuz Eylül University, Izmir, Turkey.

Tahir Saygin Ögüt (TS)

Department of Internal Medicine, Akdeniz University, Antalya, Turkey.

Veli Yazisiz (V)

Department of Internal Medicine, Akdeniz University, Antalya, Turkey.

Cemal Bes (C)

Department of Internal Medicine, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.

Ayse Celfe (A)

Department of Internal Medicine, Kocaeli University, Turkey.

Ayten Yazici (A)

Department of Internal Medicine, Kocaeli University, Turkey.

Oznur Sadioglu Cagdas (O)

Department of Internal Medicine, Kafkas University Medical Faculty, Kars, Turkey.

Andreas Kronbichler (A)

Department of Medicine, University of Cambridge School of Clinical Medicine, UK.

David Jayne (D)

Department of Medicine, University of Cambridge School of Clinical Medicine, UK.

Philipp Gauckler (P)

Department of Internal Medicine, Medical University of Innsbruck, Austria.

Alexis Regent (A)

Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.

Vitor Teixeira (V)

Hospital de Faro, Centro Hospitalar Universitário do Algarve, Faro, Portugal.

Sylvain Marchand-Adam (S)

Department of Pneumology, Centre hospitalier universitaire de Tours, France.

Pierre Duffau (P)

Department of Internal Medicine, Centre hospitalier universitaire de Bordeaux, France.

Saskia Ingen-Housz-Oro (S)

Department of Dermatology, Hôpital Henri Mondor, AP-HP, Créteil, France.

Celine Droumaguet (C)

Department of Internal Medicine, Hôpital Henri-Mondor, AP-HP, Créteil, France.

Baptiste Andre (B)

Department of Internal Medicine, Centre hospitalier universitaire de La Timone, Marseille, France.

Luminita Luca (L)

Department of Internal Medicine, Hôpital de Poitiers, France.

Sarah Lechtman (S)

Department of Internal Medicine, Hôpital Lariboisière, AP-HP, Paris, France.

Achille Aouba (A)

Department of Internal Medicine, Centre hospitalier universitaire de Caen, France.

Celine Lebas (C)

Department of Nephrology, Centre hospitalier universitaire de Lille, France.

Amélie Servettaz (A)

Department of Internal Medicine, Centre hospitalier universitaire de Reims, France.

Amandine Dernoncourt (A)

Department of Internal Medicine, Centre hospitalier universitaire d'Amiens-Picardie, France.

Marc Ruivard (M)

Department of Internal Medicine, Centre hospitalier universitaire de Clermont-Ferrand, France.

Anne-Marie Milesi (AM)

Department of Internal Medicine, Centre hospitalier de Vichy, France.

Vincent Poindron (V)

Department of Internal Medicine, Centre hospitalier universitaire de Strasbourg, France.

Patrick Jego (P)

Department of Internal Medicine, Centre hospitalier universitaire de Rennes, France.

Roberto Padoan (R)

Department of Rheumatology, University of Padova, Italy.

Paolo Delvino (P)

Department of Rheumatology, University of Pavia, Italy.

Frédéric Vandergheynst (F)

Department of Internal Medicine, Hôpital Erasme, Bruxelles, Belgique.

Christian Pagnoux (C)

Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Canada.

Elaine Yacyshyn (E)

Department of Rheumatology, University of Alberta, Edmonton, Alberta, Canada.

Peter Lamprecht (P)

Department of Rheumatology & Clinical Immunology, University of Luebeck, Germany.

Oliver Flossmann (O)

Department of Nephrology, Royal Berkshire Hospital, UK.

Xavier Puéchal (X)

Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.

Benjamin Terrier (B)

Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.

Classifications MeSH